Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.

NCT00141336 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00141336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
November 30, 1999
Completion date
July 31, 2005
Enrollment
750
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

seizure disorder, partial